Innovative RNA vaccines for tuberculosis targeting the mucosal immune system
Official title: RNA Vaccine Innovations for TB: Targeting the Mucosa
Funded at Hdt Bio Corporation · NIH-10813157 · Data updated 2026-11-12
This study is working on a new RNA vaccine to help boost the immune system's fight against tuberculosis, especially in the lungs, and it's designed to be both effective and affordable for people who need it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hdt Bio Corporation NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | April 22, 2022 |
| Project end | September 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $543,301 |
| NIH project number | 5R61AI169207-03 |
| Project ID | NIH-10813157 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would include individuals at high risk for tuberculosis infection, such as those living in endemic areas or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for tuberculosis or those who have already been vaccinated with existing TB vaccines may not receive benefit from this research.
What this research studies
This research focuses on developing a new type of RNA vaccine aimed at enhancing the immune response against tuberculosis (TB), particularly at mucosal sites such as the lungs. The approach involves using a novel RNA platform that has shown promise in previous vaccine developments, including COVID-19. By targeting specific protein antigens and utilizing advanced adjuvants, the goal is to create a more effective vaccine that can be produced cost-effectively. The research includes preclinical testing in animal models to evaluate the immune responses generated by the vaccine.
Why it matters
Potential benefit: If successful, this research could lead to a more effective TB vaccine that significantly reduces the incidence of the disease.
How similar studies have gone: Other research has shown success with RNA vaccine platforms in generating strong immune responses, particularly in the context of COVID-19, suggesting potential for similar advancements in TB vaccination.
Where this research is happening
-
Hdt Bio Corporation
Seattle, United States Active
Researchers
- Principal investigator: Reed, Steven Gregory — Hdt Bio Corporation
- Study coordinator: Reed, Steven Gregory
Related research
Other NIH-funded projects on the same topics.
-
How muscle-targeted self-replicating RNA vaccines trigger immunity
This project looks at how self-amplifying RNA vaccines delivered to muscle activate immune responses to protect people from respiratory viruses like COVID-19, RSV, and influenza.
-
Developing an RNA vaccine to enhance the immune response against HIV
This study is testing a new mRNA vaccine that aims to help your immune system fight HIV-1 by encouraging it to produce strong antibodies, using a special delivery method to make it work better.
-
How muscle-targeting RNA vaccines work against viruses
This study is testing a new kind of RNA vaccine designed to help your body fight off viral infections like COVID-19 by boosting your immune response, and it’s looking for participants to see how well it works and if it’s safe.
-
Developing treatments for enteroviruses affecting children
This study is working on developing special antibodies to help fight off enteroviruses like EV-D68, which can make young children very sick, and aims to create new treatments since there aren’t any available right now.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.